Diagnostics and Therapeutics for HIV: Global Markets

Report Code: PHM058D

Publish Date: Nov 2023

Publisher: BCC Publishing

Category: Pharmaceuticals

Download Report Overview

EXPLORE OFFERS

Explore Our Services

Already a member? Login to access this report free.

Report Highlights

The global market for HIV diagnostics and therapeutics is expected to increase from $30.4 billion in 2023 to $39.3 billion by the end of 2028, with compound annual growth rate (CAGR) of 5.3% during the forecast period of 2023-2028.

Report Includes

  • 27 data tables and 41 additional tables
  • An overview of the global markets for diagnostics and therapeutics for HIV
  • An estimate of the market’s size and analyses of global market trends, with data from 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
  • Quantification of the market potential of diagnostics and therapeutics for HIV by drug category, diagnostic test type, and region
  • Coverage of HIV timeline and milestones, HIV life cycle, its treatment and mechanism of action, and description of HIV prophylaxis
  • Evaluation of market dynamics such as drivers and restraints, current industry trends and patterns, and an assessment of the cost implications for treatments in many countries
  • Information on regional awareness programs, WHO initiatives and development of novel therapies, and discussion on rising comorbidities in HIV patients and social stigma associated with STDs
  • Coverage of ongoing research and predictions of the market’s future direction
  • Insights into the regulatory scenario for the U.S., Europe and Japan, to provide an overview of the regulations for new drug launches and diagnostic kits
  • Descriptions of the competitive landscape, product mapping, the strategic initiatives of the leading companies, including their R&D activities
  • Profiles of the key companies, including Medtronic, Abbott, Sanofi, Roche, Bio-Rad Laboratories Inc., and Danaher Corp.

Report Scope

This report organizes information from diverse sources into sections such as an overview, industry structure, diagnostic test type, treatment by drug categories, leading drug profiles and historic drug sales, regulations, reimbursements, and patents. The scope of this report includes an overview of the global market scenario for the diagnosis and treatment of HIV, with base year data from 2022, estimations for 2023 and forecasts for 2028 that are derived using projections of CAGR during the forecast period. Market value data is provided at global, regional, and country levels for treatments by drug categories. Market data for HIV diagnostics is provided for regional levels, with details on test types. Estimated values are based on companies’ total revenues. Projected and forecasted revenue values are in constant U.S. dollars that have not been adjusted for inflation.

The report forecasts the global market for HIV therapeutics by drug class. It discusses market data for nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), protease inhibitors (PIs), single tablet regimen fixed-dose combination (STR FDC), HIV integrase strand transfer inhibitors (INSTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs). The enzyme inhibitor drug class has been excluded when calculating the global HIV therapeutics market, as there are no late-stage pipeline molecules.

Diagnostic tests such as antigen- and antibody-based tests, CD4 tests and viral load tests are detailed with current and forecasted market data. Antigen- and antibody-based tests cover enzyme-linked immunosorbent assay (ELISA) tests, enzyme immunoassay (EIA) tests, rapid tests, and NAT tests; CD4 tests include tests conducted to monitor the CD4 load; and viral load tests include all PCR-based tests.

A detailed analysis illustrating market dynamics and market structure is incorporated into the report. A Porter’s Five Forces analysis and the supply and distribution chain are discussed in detail to provide an in-depth understanding of this market. The report covers the current regulations and guidelines for diagnostics and therapeutics for HIV, and it provides a survey of the top market players, detailing their business operations, segment focus, revenue, and strategy analysis. The report also features a market share analysis of these leading players, including information about product launches and pipeline products.

In terms of geography, the report analyzes the market across the following regions: North America, Europe, Asia-Pacific and Rest of the World (RoW). Key countries like the U.S., Canada, Mexico, Germany, France, UK, Italy, China, India and Japan are given special focus due to the high concentration of HIV diagnostics and therapeutics manufacturing companies and contract manufacturing organizations located in these areas.

The base year for the market data in this report is 2022, historical data is provided for 2020 and forecast data is given for 2028. Historical, base year and forecast data are provided for each market segment of the report.

Report Synopsis

Report Metrics Details
Base year considered 2022
Forecast period considered 2023-2028
Base year market size $28.8 billion
Market size forecast $39.3 billion
Growth rate CAGR of 5.3% for the forecast period of 2023-2032
Units considered $ Millions
Segments covered Therapeutic Type, Drug Category, and Region
Regions covered North America, Europe, Asia-Pacific, and Rest of the World (RoW).
Key Market Drivers
  • Growing emphasis on the R&D of HIV drugs.
  • Increase in healthcare expenditure.
  • Increasing prevalence cases and demand for ARV drugs.
Companies studied
ABBOTTASTRAZENECA
B. Braun SEBD
BIOCONBIO-RAD LABORATORIES INC.
BOEHRINGER INGELHEIM INTERNATIONAL GMBHDANAHER CORP.
DEXCOM INC.INSULET CORP.
JOHNSON & JOHNSON SERVICES INC.LIFESCAN IP HOLDINGS LLC.
LILLYMEDTRONIC
MERCK & CO. INC.NOVA BIOMEDICAL
NOVARTIS AGNOVO NORDISK A/S
QIAGENF. HOFFMANN-LA ROCHE LTD.
SANOFISIEMENS HEALTHINEERS AG
TERUMO CORP.THERMO FISHER SCIENTIFIC INC.
YPSOMED
Need a custom data table, graph, region, segment, companies or complete report? CUSTOMIZE NOW

Frequently Asked Questions (FAQs)

The global market for diagnostics is projected to grow from $4.1 billion in 2022 to $7.1 billion in 2028 at a compound annual growth rate (CAGR) of 9.5% during the forecast period. The therapeutics is projected to grow from $28.8 billion in 2022 to $39.3 billion in 2028, at a compound annual growth rate (CAGR) of 5.3% during the forecast period.
The key factors driving the growth of the global market for diagnostics and therapeutics of HIV:
  • Increase in popularity of home-use HIV diagnosis devices.
  • Government initiatives
  • Technological advancements
The global market for HIV diagnostics and Therapeutics market is segmented based on drug category, device, and geographical region.
North American segment will dominate the market by the end of 2028.
The major players include AstraZeneca, Novartis, Pfizer, Roche, and Thermo Fisher Scientific.

Analyst Credentials

Kalyani Kottapenta – Assistant Manager, Life Sciences
Kalyani Kottapenta is a research professional with nine years of experience in the life sciences and healthcare industry. Her expertise in qualitative and quantitative market information, including market dynamics like market sizing, advanced excel based market modeling, data analysis, forecasting, company share analysis, and competitive landscape assessment of the medical device industry, developing custom reports. She holds a master’s degree in Microbiology and a bachelor’s in Biotechnology and Chemistry.

Let us assist you! Our analysts are ready to tailor this report to your specific need. Talk to Our Analyst

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesMember Price
Full Report: Diagnostics and Therapeutics for HIV: Global Markets186Free
Chapter- 1: Introduction6Free
Chapter- 2: Summary and Highlights3Free
Chapter- 3: Market and Technology Background10Free
Chapter- 4: Global Industry Trends6Free
Chapter- 5: Market Breakdown by HIV Therapeutic20Free
Chapter- 6: HIV Market by ARV Drug Category22Free
Chapter- 7: Emerging Technologies2Free
Chapter- 8: Evaluation of Market for HIV Diagnostics14Free
Chapter- 9: Patents17Free
Chapter- 10: Competitive Landscape4Free
Chapter- 11: Company Profiles82Free
Published - Nov-2018| Analyst - BCC Publishing| Code - PHM058C

Report Highlights

The global HIV therapeutics market should reach $27.1 billion by 2023 from $22.0 billion in 2018 at a compound annual growth rate (CAGR) of 4.3% for the period of 2018 to 2023.

Report Includes

  • 37 data tables and 49 additional tables
  • Industry analysis of diagnostics and therapeutics for the HIV disease, and its global markets
  • Analyses of global market trends with data from 2017, estimates for 2018, and projections of compound annual growth rates (CAGRs) through 2023
  • Characterization and quantification of market potential for therapeutic drugs for HIV virus by drug categories, diagnostic test types, application sectors and geographical regions
  • Country-specific data and analysis for United States, Canada, Mexico, Japan, China, India, France, Germany, U.K., Italy, Spain and Middle East and Africa
  • Evaluation of the market dynamics such as drivers, restraints and current industry trends and patterns
  • Discussion of the regulatory scenario for United States, Europe, and Japan to provide an overview of the regulations for new drug launches and diagnostic kits
  • Examination of cost implications for treatments across a range of countries
  • A look at ongoing research and the future direction of the market
  • Assessment of the competitive landscape and discussion of the major manufacturers involved in the HIV therapeutics market, key developments and product offerings, including Abbott Laboratories, Bio-Rad Laboratories, Cipla Inc., GlaxoSmithKline, Merck & Co., Siemens Healthineers and Thermo Fisher Scientific
Published - Apr-2014| Analyst - Kritika Chaudhari| Code - PHM058B

Report Highlights

The global market for HIV therapeutics is expected to grow to $18.2 billion in 2013 and $19.6 in 2018, with a compound annual growth rate (CAGR) of 1.5%.

Report Includes

  • An overview of the global market for HIV therapeutics and diagnostics
  • Analyses of global market trends, with data from 2013, and estimates and projections of CAGRs through 2018.
  • Discussion of improvements in advanced treatments and diagnostic methods.
  • Examination of cost implications for treatments accross a wide range of countries
  • A look at ongoing research and the future direction of the market.

Published - Mar-2011| Analyst - Paul Evers| Code - PHM058A

Report Highlights

The global HIV/AIDS market, including branded products and generics, was valued at $11.3 billion in 2010. This market is expected to reach $11.8 billion in 2011 and increase at a 4.6% compound annual growth rate (CAGR) over the 2011-2016 forecast period to reach $14.1 billion in 2016.

Related Reports

Flow Cytometry: Products, Technologies and Global Markets

Published - Jun 2024 | Publisher - BCC Publishing | Code - BIO085F

The global market for flow cytometry products is expected to grow from $5.2 billion in 2023 to $8.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 8.2% from 2024 to 2029.

Companion Diagnostics: Technologies and Markets

Published - May 2024 | Publisher - BCC Publishing | Code - BIO077F

The global market for companion diagnostics is estimated to increase from $7.6 billion in 2023 to reach $15.4 billion by 2028, at a compound annual growth rate (CAGR) of 15.2% from 2023 through 2028.

Global Markets for Vaccine Technologies

Published - Feb 2024 | Publisher - BCC Publishing | Code - PHM014K

The global market for vaccine technologies is expected to grow from $45.0 billion in 2023 to $65.3 billion by the end of 2028, at a compound annual growth rate (CAGR) of 7.8% from 2023 to 2028.

Recent Reports

Laboratory Animal Models, 3D Cultures, and Organoids: Global Markets

Published - Dec 2024 | Publisher - BCC Publishing | Code - PHM204C

The global market for laboratory animal models, 3D cultures, and organoids is estimated to increase from $2.8 billion in 2024 to reach $5.0 billion by 2029, at a compound annual growth rate (CAGR) of 12.5% from 2024 through 2029.

Rare Disease Diagnostics: Technologies and Global Markets

Published - Dec 2024 | Publisher - BCC Publishing | Code - PHM227B

The global market for rare disease diagnostics is estimated to increase from $21.6 billion in 2024 to reach $34.7 billion by 2029, at a compound annual growth rate (CAGR) of 9.9% from 2024 through 2029.

Breakthrough Therapies: Market Dynamics and Investment Opportunities

Published - Dec 2024 | Publisher - BCC Publishing | Code - PHM176B

The global market for breakthrough therapy drugs was valued at $133.3 billion in 2023. This market is expected to grow from $150.6 billion in 2024 to $287.5 billion by 2029, at a compound annual growth rate (CAGR) of 13.8% from 2024 to 2029.

Softgel Capsules: Global Markets

Published - Nov 2024 | Publisher - BCC Publishing | Code - PHM244B

The global market for softgel capsules was valued at $7.4 billion in 2023. The market is expected to grow from $7.9 billion in 2024 to $11.5 billion by 2029, at a compound annual growth rate, or CAGR, of 7.7% from 2024 through 2029.

Global Market Opportunities and Competitive Landscape for CDMO

Published - Nov 2024 | Publisher - BCC Publishing | Code - PHM238B

The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.

Top Trending Reports

Single-use Technologies for Biopharmaceuticals: Global Markets

Published - Nov 2024 | Publisher - BCC Publishing | Code - BIO099F

The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.

Cell and Gene Therapy Tools, and Reagents: Global Markets

Published - Nov 2024 | Publisher - BCC Publishing | Code - BIO208C

The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.

Medical Devices Industry: Competitive Landscape

Published - Nov 2024 | Publisher - BCC Publishing | Code - MDS010C

The global market for medical devices is estimated to increase from 810.4 billion in 2024 to reach $1.3 trillion by 2029, at a compound annual growth rate (CAGR) of 9.8% from 2024 through 2029.

Global Market Opportunities and Competitive Landscape for CDMO

Published - Nov 2024 | Publisher - BCC Publishing | Code - PHM238B

The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.

Chronic Disease Management: Therapeutics, Device Technologies and Global Markets

Published - Oct 2024 | Publisher - BCC Publishing | Code - HLC239C

The global market for chronic disease management therapeutics and device technologies was valued at $675.0 billion in 2023. It is projected to grow from $726.3 billion in 2024 to $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 8.1% from 2024 through 2029.

Become A Member

BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.

Find Out More

Custom Consulting

BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.

Customize Now

Scorecard

The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.

Find Out More

Innovation Spotlight

Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.

Find Out More
Diagnostics and Therapeutics for HIV: Global Markets
Sample Report